# US 10,245,289 B2 · Treatment and prophylaxis for lupus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,289 B2
- Document ID: US10245289B2
- Status: Granted
- Kind: B2
- Application number: 15/378,779
- Filed: 2016-12-14
- Published: 2017-06-22
- Granted: 2019-04-02
- Earliest claimed: 2015-12-17
- Assignees: NuBiome, Inc.
- Applicants: NuBiome, Inc.
- Inventors: Brian C. Lue
- Web page: https://patentgrep.com/patent/US10245289B2

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 38/48: acting on peptide bonds (3.4)
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- C12Y 304/21062: Subtilisin (3.4.21.62)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

An embodiment is a method of preventing, mitigating or treating Lupus that includes administering an effective amount of a medicament to a human comprised of Lactobacillus bulgaricus B-30892 and/or a supernatant resulting from culturing Lactobacillus bulgaricus B-30892 and/or bioactive materials resulting from culturing Lactobacillus bulgaricus B-30892 to prevent, mitigate or treat Lupus.

## Claims

### Claim 1

A method of mitigating or treating Lupus comprises:
administering an effective amount of a medicament to the gastrointestinal tract of a human comprised of Lactobacillus bulgaricus B-30892 and/or a supernatant resulting from culturing Lactobacillus bulgaricus B-30892 and/or bioactive materials resulting from culturing Lactobacillus bulgaricus B-30892 to mitigate or treat Lupus.

### Claim 2 (depends on 1)

The method of claim 1 wherein the medicament further comprises oligopeptidase F (PepF).

### Claim 3 (depends on 1)

The method of claim 1 wherein the medicament further comprises endopeptidase O (PepO).

### Claim 4 (depends on 1)

The method of claim 1 wherein the medicament further comprises endopeptidase O2 (PepO2).

### Claim 5 (depends on 1)

The method of claim 1 wherein the medicament further comprises subtilisin.